Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy
AbstractPurposeTo evaluate the association of various gene expression assays with pathologic complete response (pCR) in the setting of neoadjuvant chemotherapy among patients with breast cancerMethodsThe National Cancer Database (NCDB) was queried for women diagnosed between 2010 and 2017 with stage I-III breast cancer who underwent neoadjuvant chemotherapy and either 21-gene recurrence score (RS) or 70-gene signature (GS). Logistic multivariable analysis (MVA) was performed to identify variables associated with pCR.ResultsA total of 3009 patients met our inclusion criteria. The median follow up was 48.0 months (interquartile range 32.2–66.7 months). On logistic MVA for all patients, those with a high risk from GS (adjusted odds ratio [aOR] 3.23, 95% confidence interval [CI] 1.49–8.13,p = 0.006) or with RS ≥ 31 (aOR 1.99, 95% CI 1.41–2.82,p
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211035037. doi: 10.1177/15330338211035037.ABSTRACTBACKGROUND: Oncotype Dx (ODx) is a genomic assay which estimates the risk of distant recurrence and predicts adjuvant chemotherapy benefit in early stage breast cancer patients. Most ODx data is derived from excisional specimens.AIM: We assess the utility of ODx on core needle biopsies (CNB) and measure its impact on neoadjuvant treatment decisions, particularly in patients with clinically complicated situations.METHODS: Consecutive ODx results on breast CNBs with invasive carcinoma from 2012-2020 at 3 tertiary care hospital...
ConclusionSix cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.
Clin Breast Cancer. 2021 Sep 29:S1526-8209(21)00288-3. doi: 10.1016/j.clbc.2021.09.010. Online ahead of print.NO ABSTRACTPMID:34688554 | DOI:10.1016/j.clbc.2021.09.010
This study aims to observe and analyze the effect of diffusion weighted magnetic resonance imaging (MRI) on the patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
CONCLUSIONS: Our results highlight the variable expression of senescence- and apoptosis-associated markers in breast tumors (despite the shared somatic genetic background) and invites a large-scale assessment of both senescence and apoptosis in breast cancer tissue in vivo and their contribution to the pathological response and overall survival.PMID:34677245 | PMC:PMC8535022 | DOI:10.3390/curroncol28050327
We report on a 52-year-old woman with breast cancer admitted in our institution for onycholysis. Because of the stage and histology of breast cancer, neoadjuvant chemotherapy was initiated. The patient received 8 cycles of Taxotere and Adriamycin (AT), and she underwent a modified radical mastectomy. Three months later, the patient developed evidence of onycholysis, involving all the fingernails. We observed the following changes in nails of all the digits in both hands: onycholysis, dystrophy, oedema, and exudate. Nail scraping and purulent discharge were collected and cultured on Sabouraud medium. Physical features of th...
Condition: Triple Negative Breast Cancer (TNBC) Interventions: Drug: Camrelizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel Sponsor: Aiping Shi Recruiting
Oncol Lett. 2021 Dec;22(6):819. doi: 10.3892/ol.2021.13080. Epub 2021 Oct 5.ABSTRACTTriple-negative breast cancer (TNBC) is characterized by aggressive clinicopathological features and is associated with a poor prognosis. Identifying patients that are non-responsive to chemotherapy remains a critical goal for effective personalized therapies. In the present study, the predictive value of exosomal microRNAs (miRNAs) was investigated in patients with TNBC. Exosomes were isolated from patients with TNBC undergoing neoadjuvant chemotherapy. Microarray-based miRNA profiles were compared between patients with pathological comple...
Ann Surg Oncol. 2021 Oct 20. doi: 10.1245/s10434-021-10830-4. Online ahead of print.NO ABSTRACTPMID:34671883 | DOI:10.1245/s10434-021-10830-4